Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Patient-derived organoids (PDOs) model treatment response of metastatic gastrointestinal cancers.

ABSTRACT: Patient-derived organoids (PDOs) model treatment response of metastatic gastrointestinal cancers.

PROVIDER: PRJNA427119 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Culture media composition influences patient-derived organoids ability to predict therapeutic response in gastrointestinal cancers

Project description:In this study, we have generated patient-derived organoids (PDOs) from primary and metastatic lesions of gastrointestinal cancers, including pancreatic ductal adenocarcinoma, colorectal adenocarcinoma, and cholangiocarcinoma and evaluated their ability to predict donor tumor drug response. Specifically, we examined individual PDO responses to therapeutic agents with the observed clinical responses of donor patients to the same treatments and demonstrated an approximately 80% concordance rate. Importantly, we found a profound influence of culture media in PDOs phenotypes, we observed a significant difference in response to common PDAC chemotherapies, distinct morphologies, and transcriptomes between media in the same PDOs. These studies demonstrate the important role of culture media when using PDOs to inform patient care and predict response across a spectrum of GI cancers. We compared transcriptome data from pancreatic ductal adenocarcinoma patient-derived organoids in two media (WNT and PaTOM).

2022-10-12 | GSE212014 | GEO

Patient-derived organoids model treatment response of metastatic gastrointestinal cancers.

Project description: Not available

| S-EPMC6112415 | biostudies-literature

RNA-seq analysis on organoids derived from metastatic tumor patients

Project description:To evaluate the efficiency of apatinib on vascularized patient-derived tumor organoids (PDTOs)-on-a-chip derived from patients with metastatic tumors, we conducted RNA-seq analysis on organoids derived from patients whom had metastatic tumors. Specifically, we extracted RNA for sequencing from tumor cells of organoids either cultured alone or co-cultured with MVs with or without apatinib treatment

2024-04-27 | GSE264645 | GEO

Patient-derived organoids (PDOs) model treatment response of metastatic gastrointestinal cancers.

Project description:We report RNAseq data from subsequent passages of five organoid cultures.

2017-12-22 | GSE108391 | GEO

Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: a real-world study

Project description:Using patient derived lung cancer organoids to predict clinical response and find theraputic mechanisms

2022-09-26 | PXD037076 | iProX

Expression data from CRC patient-derived organoids

Project description:Colorectal cancer (CRC) is a commonly occurring cancer worldwide. Metastasis and recurrence are the major causes of cancer-related death. CRC progression is a multistep process, and extensive efforts have been made to identify the genomic and transcriptomic alterations that occur during this process. However, whether primary tumors and metastatic lesions possess distinct biological features remains unclear. We established 74 patient-derived organoids (PDOs) from primary tumors and patient-matched metastatic and recurrent lesions.

2021-04-01 | GSE128213 | GEO

Patient-derived organoids for precise medicine in gastric cancer

Project description:Gastric cancer (GC) is a challenging malignant disease among gastrointestinal tumors. The clinical treatments for GC include surgery, neoadjuvant therapy and adjuvant chemotherapy. As patients’ response to chemotherapeutic drugs varies, an approach to predict the efficacy of chemotherapeutic treatment is urgently needed. Here, a biorepository of 17 human gastric tumor organoids (GTOs) and 9 normal organoids (GNOs) derived from GC patients was established, which contains the intestinal, diffuse and mixed-type of GC. GTOs retained morphologic, histopathological and genetic features of the tumors from which they were derived, and patient-derived organoid xenograft model indicated tumorigenicity of organoids. GTOs responses to clinically respective chemotherapy treatment positively correlated with the individual patient’s clinical response. Meanwhile, GNOs, which maintained original characteristics of corresponding tissues, could be separated from GTOs. The use of GNOs predicted the cytotoxic effect of chemotherapy on the organism. Our study implies that patient-derived organoids predict GC patient responses to chemotherapy and provide a solution for personalized treatment.

2024-03-10 | GSE235912 | GEO

Cancer gene discovery in mouse gastrointestinal cancers

Project description:Cancer gene discovery in mouse gastrointestinal cancers

| PRJEB2471 | ENA

Proteomics profiling in primary tumors of metastatic and non-metastatic breast cancers

Project description:Analysis of different proteomics profile in primary tumors of metastatic and non-metastatic breast cancers.

2023-03-09 | PXD037288 | Pride

Transcriptomic profiling of patient-derived endometrial cancer organoids (Berg HF)

Project description:Patient-derived endometrial cancer organoids. The data was used to compare gene expression profile between organoids, and to explore whether an organoid-derived gene signature could predict disease outcomes in independent patient cohorts.

2021-07-16 | E-MTAB-10664 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data